CatalystFDA/Bio

Arrowhead’s plozasiran cuts pancreatitis events in Phase 3 studies

Phase 3 data show plozasiran reduces pancreatitis events, a key efficacy endpoint.

What changed

Why it matters

Phase 3 data show plozasiran reduces pancreatitis events, a key efficacy endpoint.

Sources